Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Effects of Multiple Nasal Exposures to House Dust Mite Allergen on Nasal and Body Inflammation and Airway Sensitivity
- Conditions
- Allergic Rhinitis
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2008-07-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 18
- Registration Number
- NCT00513487
- Locations
- 🇦🇺
Novartis Investigative site, Sydney, Australia
A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation
- Conditions
- Irritable Bowel Syndrome With ConstipationChronic Idiopathic Constipation
- First Posted Date
- 2007-08-06
- Last Posted Date
- 2010-11-18
- Lead Sponsor
- Novartis
- Registration Number
- NCT00511771
Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: NVA237 100 µgDrug: NVA237 200 µgDrug: Placebo
- First Posted Date
- 2007-08-02
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 281
- Registration Number
- NCT00510510
- Locations
- 🇹🇷
Novartis investigative site, Istanbul, Turkey
Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 80
- Registration Number
- NCT00504595
- Locations
- 🇨🇭
Novartis Investigative site, Bern, Switzerland
🇹🇷Novartis investigative site, Istanbul, Turkey
Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2009-08-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 11
- Registration Number
- NCT00505089
- Locations
- 🇵🇱
Novartis Investigative Site, Grodzisk Mazowiecki, Poland
🇳🇱Novartis investigative site, Leiden, Netherlands
🇵🇱Novartis Investigator Site, Poznan, Poland
Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
- Conditions
- Secondary to Age-related Macular Degeneration (AMD)Subfoveal Choroidal Neovascularization (CNV)
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 234
- Registration Number
- NCT00504959
- Locations
- 🇹🇷
Novartis Investigative SIte, Ankara, Turkey
🇦🇺Novartis Investigational Site, Melbourne, Australia
🇬🇧Novartis Investigative Site, Wolverhampton, United Kingdom
Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration
- Conditions
- Wet Age-Related Macular Degeneration
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 20
- Registration Number
- NCT00503022
Tolerability, Safety and Efficacy of SAD448 in Subjects With Ocular Hypertension
- Conditions
- Ocular Hypertension
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2008-04-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 80
- Registration Number
- NCT00503360
- Locations
- 🇦🇺
Novartis Investigative site, Sydney, Australia, Sydney, Australia
Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.
- Conditions
- Asthma
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2011-06-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 155
- Registration Number
- NCT00500539
- Locations
- 🇺🇸
Kansas City Allergy & Asthma, Overland Park, Kansas, United States
🇺🇸Allergy, Asthma and Clinical Immunology, Brick, New Jersey, United States
🇺🇸Asthma & Allergy Research of NJ, Inc., Mt. Laurel, New Jersey, United States
Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension
- Conditions
- HypertensionAbdominal Obesity
- Interventions
- First Posted Date
- 2007-07-10
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 46
- Registration Number
- NCT00498433
- Locations
- 🇩🇪
Novartis Investigative Site, Hannover, Germany